Updates are available Correction dated 2021-05-27
Click to view Correction: https://doi.org/10.1007/s10147-021-01940-w
Updates are available Correction dated 2022-09-27
Click to view Correction: https://doi.org/10.1007/s10147-022-02237-2
-
Authors
Aogi, Kenjiro https://orcid.org/0000-0001-6512-7051
Watanabe, Kenichi
Kitada, Masahiro
Sangai, Takafumi
Ohtani, Shoichiro
Aruga, Tomoyuki
Kawaguchi, Hidetoshi
Fujisawa, Tomomi
Maeda, Shigeto
Morimoto, Takashi
Sato, Nobuaki
Takao, Shintaro
Morita, Satoshi
Masuda, Norikazu
Toi, Masakazu
Ohno, Shinji
- License Information
-
More Information
Article History
Received: 20 December 2020
Accepted: 3 April 2021
First Online: 23 April 2021
Change Date: 27 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10147-021-01940-w
Change Date: 27 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10147-022-02237-2
Declarations
:
: Kenjiro Aogi received honoraria from Chugai, Eisai, AstraZeneca, Taiho, Novartis, Daiichi Sankyo, Mochida, Ono and Eli Lilly, research funding from Chugai, Eisai, Takeda and Sanofi; Takashi Sangai has received research funding from Eisai; Shoichiro Ohtani received honoraria from Chugai, Eli Lilly, AstraZeneca, Pfizer and Eisai; Tomoyuki Aruga received honoraria from Eisai; Hidetoshi Kawaguchi received honoraria from Pfizer, Chugai, AstraZeneca, Eli Lilly, Kyowa-Kirin, Novartis, Taiho and Takeda; Nobuaki Sato has received remuneration from Chugai, Taiho and Kyowa-Kirin; Satoshi Morita received honoraria from AstraZeneca, Bristol-Myers Squibb Company, Chugai, Eisai, Eli Lilly, MSD, Pfizer and Taiho; Norikazu Masuda received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, Takeda, research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, Nippon Kayaku, Daiichi Sankyo; Masakazu Toi received honoraria from Eisai, Taiho, Takeda, Kyowa-Kirin, Chugai, Daiichi Sankyo, AstraZeneca, Pfizer and Eli Lilly, research funding from Eisai, Taiho, Takeda, Kyowa-Kirin, Chugai, Daiichi Sankyo, AstraZeneca and Pfizer, others for Board of directors of JBCRG association, Kyoto Breast Cancer Research Network; Shinji Ohno has received honoraria from AstraZeneca, Eisai, Pfizer, Chugai and Eli Lilly, research funding from Eisai and Taiho; Kenichi Watanabe, Masahiro Kitada, Tomomi Fujisawa, Shigeto Maeda, Shintaro Takao and Takashi Morimoto has no conflict of interest. Conflict of interest refers to any relationship that may influence the study results and includes financial and personal factors.
